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Context
Phase I
1.

2.

3.
4.

Vaccines are given to
humans; small
sample size (<100)
Given to healthy
humans (ensure the
eﬃcacy of the
vaccine)
Analyze side effects
Dosage: (Upper limit
vs lower limit)

Phase II
1.
2.

3.

Sample size
increases (100-1000)
More representative
sample group (age,
gender, underlying
diseases); not just
healthy individuals
Monitoring side
effects based on
determined dosage

Phase III
1.

2.

3.

Large sample size
(13, 060
participants)
Still matching
demographics of
population
Monitoring
symptoms

Vocabulary Words
Randomized- Participants had an equal probability of being placed into control vs experimental
group
Multicenter- Trials took place at multiple centers (Brazil)
Endpoint driven- At the end of the clinical trial, researchers can use the statistics to conclude
whether the intervention technique was beneﬁcial
Double blind- Neither the participants nor the experimenter are aware of which group the
participants fall into (Control group vs. experimental group); minimize bias
Placebo controlled- One group is given a placebo vs the other receiving treatment
Adverse reaction- Any reactions that have a casual relationship to vaccination

Sinovac Vaccine
●

●

Vaccines work by imitating an infection (usually involving inactivated viral
components); helps acquire immunity; production of T-lymphocytes (destroy
infected cells and make antibodies) and B-lymphocytes (target pathogens)
Sinovac Vaccine
○
○
○
○
○

Manufactured by Sinovac Life Sciences (Beijing, China)
Inactivated vaccine- genetic material of the pathogen is eliminated by heat,
radiation, or chemicals; cannot replicate or cause illness
Immune response is not as strong as live attenuated vaccines (virus is
weakened; can’t cause major illness but can still replicate)
Less long lasting
Requires booster doses

Design
Step 1
Qualiﬁcations
-

-

18 years or older, both genders,
healthy/underlying diseases
Health care professionals in
close contact with COVID-19
patients
Pregnant women, those
breastfeeding, or plans to
conceive within three months
of receiving vaccine were
excluded

Step 2
Assignments
-

-

Randomized based
on age (18-59 years
and 60 years and
older)
Two randomization
groups
- 11,800 (18-59
year-old)
- 1, 260 elderly
(above 60
year-old)

Step 2 Continued
Assignments (cont.)
-

-

Half of the participants in
each group were given the
treatment and half were
given the placebo
Used a centralized
randomization system for
assignment

Design
Step 3
Experimentation
-

-

-

Vaccine includes 3 ug/ 0.5
mL of the inactivated
SARS-CoV-2 virus
Adjuvant- aluminium
hydroxide (helps boost the
immune response)
- Antigen remains for a
longer period of time
Placebo- aluminum hydroxide
in 0.5 mL solution

Step 5

Step 4
-

Schedule
-

Vaccine and placebo
(0.5mL doses) were given
as IM injections (deltoid)
in a two week interval

Outcomes
-

-

-

Assessment of eﬃcacy based on
WHO standards (protection level
above 50%)
Primary eﬃcacy endpointincidence of symptomatic cases
of COVID-19 two weeks after
second injection (diagnosed
clinically)
Primary safety endpoint- any
adverse reactions one week after
vaccination in both groups

Discussion Questions
1.

As the vaccine supply increases, do you think the people receiving the
vaccine should be given a choice as to which one they want to receive?

2.

What are your thoughts on the smaller sample size of senior citizens (1,260
participants above 60) compared to the other group (11,800 18-59 year-old).
Should this Phase III trial have included more senior citizens because they
are the most vulnerable group?

3.

Moderna has started testing their vaccines on babies and young children,
do you think that they should’ve started with the older children ﬁrst? Since
young children typically do not get severely ill.

1.
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